Imricor Medical Systems (ASX:IMR) - Aandelenkoers, Nieuws & Analyse

IMR Overzicht aandelen

Imricor Medical Systems, Inc., een bedrijf voor medische apparatuur, ontwerpt, produceert, verkoopt en distribueert producten die compatibel zijn met MRI (Magnetic Resonance Imaging) voor hartkatheterablatieprocedures in de Verenigde Staten.

Over het bedrijf

IMR fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 88.49% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $824K )

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Imricor Medical Systems, Inc. Concurrenten

Anteris Technologies

ASX:AVR

AU$211.4m

Cyclopharm

ASX:CYC

AU$156.7m

Optiscan Imaging

ASX:OIL

AU$154.5m

Respiri

ASX:RSH

AU$111.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Imricor Medical Systems
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.74
52 Week Hoogtepunt	AU$0.82
52 Week Laag	AU$0.41
Bèta	0.25
11 maand verandering	34.55%
3 maanden verandering	39.62%
1 Jaar Verandering	24.37%
33 jaar verandering	-43.08%
5 jaar verandering	-38.33%
Verandering sinds IPO	-48.97%

Recent nieuws en updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Jan 24

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Dec 02

What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition

Aug 18

Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)

Jun 25

Rendement voor aandeelhouders

	IMR	AU Medical Equipment	AU Markt
7D	16.5%	2.9%	2.0%
1Y	24.4%	15.5%	18.3%

Rendement versus industrie: IMR overtrof de Australian Medical Equipment industrie, die het afgelopen jaar een rendement 15.5 % opleverde.

Rendement versus markt: IMR overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 18.3 %.

Prijsvolatiliteit

Is IMR's price volatile compared to industry and market?
IMR volatility
IMR Average Weekly Movement	11.7%
Medical Equipment Industry Average Movement	9.9%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

Stabiele aandelenkoers: IMR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van IMR is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	n/a	Steve Wedan	www.imricor.com

Imricor Medical Systems, Inc, een bedrijf voor medische apparatuur, ontwerpt, produceert, verkoopt en distribueert producten die compatibel zijn met MRI (Magnetic Resonance Imaging) voor hartkatheterablatieprocedures in de Verenigde Staten. Het belangrijkste product van het bedrijf is het Advantage-MR EP Recorder/Stimulator systeem, een EP-opnamesysteem en hartstimulator. De producten van het bedrijf omvatten ook de Vision-MR Ablation Catheter, die wordt gebruikt als indicatie voor de behandeling van type I atriale flutter; en de Vision-MR Dispersive Electrode die wordt gebruikt om wervelstromen te minimaliseren die worden geïnduceerd op de geleidende pads tijdens MR-scannen.

Imricor Medical Systems, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Imricor Medical Systems zich tot de beurswaarde?
IMR fundamentele statistieken
Marktkapitalisatie	AU$199.93m
Inkomsten(TTM)	-AU$30.55m
Inkomsten(TTM)	AU$1.24m

160.9x

P/S-verhouding

-6.5x

Koers/Winstverhouding

Is IMR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMR resultatenrekening (TTM)
Inkomsten	US$824.32k
Kosten van inkomsten	US$1.74m
Brutowinst	-US$913.44k
Overige uitgaven	US$19.35m
Inkomsten	-US$20.26m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.075
Brutomarge	-110.81%
Nettowinstmarge	-2,458.30%
Schuld/Eigen Vermogen Verhouding	-126.8%

Hoe presteerde IMR op de lange termijn?

Bekijk historische prestaties en vergelijking

IMR Overzicht aandelen

Beloningen

Risicoanalyse

Imricor Medical Systems, Inc. Concurrenten

ASX:AVR

AU$211.4m

ASX:CYC

AU$156.7m

ASX:OIL

AU$154.5m

ASX:RSH

AU$111.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Recent updates

Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

New major risk - Share price stability

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 57%

Imricor Medical Systems, Inc. Announces Executive Changes

Consensus forecasts updated

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Consensus forecasts updated

We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.16

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021